Back to top

dna-sequencing: Archive

Zacks Equity Research

Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

HAENegative Net Change DXCMPositive Net Change PODDPositive Net Change EXASNegative Net Change